Hackensack, NJ (PRWEB) September 21, 2008
Progenitor Cell Therapy, LLC (PCT) announced today a number of key personnel decisions. "These changes," states PCT President Dr. Robert A. Preti, "are part of our overall human resources strategy to ensure that PCT's core personnel base continues to strengthen and keep pace with our facilities and business expansion."
Giovanni D'Alia joined PCT in July 2008 as Director, Manufacturing Operations (East Coast). He is a successful staff manager with a record of cross-functional accomplishments, involving internal and external collaborations. Mr. D'Alia has demonstrated successful leadership in team environments from start-up biotech operations to large pharmaceutical companies. He has a Master of Science degree in Biology from William Paterson University and continues coursework toward a Master of Business Administration.
Prior to joining PCT, Giovanni held managerial positions at Elusys Therapeutics Inc., the most recent of which was Director of Manufacturing and Analytical Sciences. Previously he was a senior research scientist at Hoffman La-Roche, in operations technical support with Roche Molecular Systems, and held manufacturing oversight positions with Wyeth Lederle Vaccines & Pediatrics and LigoChem Inc.
In addition to the hiring of Mr. D'Alia, PCT also announced today the promotion of two other personnel.
Karin Abitorabi (M.S.) is now a Senior Scientist, Process Development - a promotion from her previous position as Scientist, Process Development. While at PCT, Ms. Abitorabi has assumed an ever-increasing level of lead support in process development projects as PCT assists clients in developing their cell therapy products for clinical and/or commercial manufacturing production.
Marta Schilling has been promoted to Senior Director, Manufacturing Operations and Process Development (West Coast). Ms. Schilling's promotion is a reflection of her past performance as Director of Manufacturing Operations (West Coast), her dedication, considerable management skills, and increased oversight of Materials Control and Process Development at PCT's Mountain View facility.
About Progenitor Cell Therapy, LLC
Progenitor Cell Therapy, LLC (PCT) is a client-based company providing cell therapy service solutions for the research, development, manufacturing, and commercialization of cell-based therapies. With its cell therapy manufacturing facilities and team of experienced professionals, PCT provides current Good Manufacturing Practices cGMP-compliant services for pre-clinical and clinical development, manufacturing, and eventual commercialization of cellular therapies for clients throughout the world. For more information, please visit http://www.progenitorcelltherapy.com.
George S. Goldberger, Chief Business Officer
(201) 883-5314 ggoldberger(at)progenitorcelltherapy.com
This press release does not constitute an offer to sell, or a solicitation of any offer to buy any securities of Progenitor Cell Therapy. In addition, certain of the statements in this press release are forward-looking statements relating to such matters as anticipated financial performance, business prospects, technological developments, new products, research, and development activities and similar matters. These statements involve known and unknown risks, uncertainties, and other factors that may cause the company or its industry's actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "intend," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue" or the negative of such terms or other comparable terminology. Forward-looking statements are only predictions. Actual events or results may differ materially. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance, or achievements. Moreover, neither the company nor any other person assumes responsibility for the accuracy and completeness of such statements. The company is under no duty to update any of the forward-looking statements after the date of this press release to conform such statements to actual results.